In clinical use, LIMA1 IHC staining combined with current HNSCC diagnostic routines would constitute a simple and affordable upfront HNSCC diagnostic method for planning of the individualized patient therapy and follow-up strategies based on the tumor aggressiveness. This evidence concerns the gene LIMA1 and neoplasm.